Clinical Trial Update: Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed immunogenicity and safety of the Hib vaccine LBVH0101 in healthy infants at 2, 4, and 6 months; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection

Drugs mentioned

• LBVH0101

Snippet

Sponsor: LG Life Sciences | Conditions: Infectious Disease by Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED